Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00920543 · ClinicalTrials.gov registry record · Phase 4
GSK BHR Study (Sont)
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 464
- Enrollment target
NCT00920543: Completed Phase 4 study, sponsored by GlaxoSmithKline.
NCT00920543 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 464 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (10% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00920543, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 464 participants
- Enrollment target
Study Summary
The purpose of this study was to determine whether asthma control and reduced bronchial hyperresponsiveness could be achieved and maintained at a lower dose of inhaled corticosteroids with ADVAIR DISKUS twice-daily or FP twice-daily in adult and adolescent subjects with persistent asthma
Interventions
- DRUG Placebo
- DRUG FP 100mcg
- DRUG FP 500mcg
- DRUG FP 250mcg
- DRUG FSC 100/50mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 464 participants |
| Start Date | 2003-02 |
| Est. Completion | 2004-10 |
| Phase | Phase 4 |
What the finished NCT00920543 record still lists
NCT00920543 is an interventional study that assigns participants to a tested intervention. The registered 464 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (10% lower).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00920543 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00920543 about?
NCT00920543 is a clinical study titled "GSK BHR Study (Sont)". The purpose of this study was to determine whether asthma control and reduced bronchial hyperresponsiveness could be achieved and maintained at a lower dose of inhaled corticosteroids with ADVAIR DISKUS twice-daily or FP twice-daily in adult and adolescent subjects with persistent asthma
What is the current status of trial NCT00920543?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 464 participants. The study started on 2003-02. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00920543?
The interventions under investigation include: Placebo (DRUG), FP 100mcg (DRUG), FP 500mcg (DRUG), FP 250mcg (DRUG), FSC 100/50mcg (DRUG).
Who is sponsoring clinical trial NCT00920543?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00920543's enrollment target sits among peer trials
464 183rd of 2000 higher than 1,818 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04787744 · 464 participants · Phase 2
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
- NCT04855656 · 464 participants · Phase 1
Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
- NCT06283927 · 464 participants
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
- NCT06444295 · 464 participants · NA
Testing the Impact of Thrive App Versions on Alcohol Use and Posttraumatic Stress After Recent Sexual Assault
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia